AVBP
Price:
$31.02
Market Cap:
$1.44B
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-hel...[Read more]
Industry
Biotechnology
IPO Date
2024-01-26
Stock Exchange
NASDAQ
Ticker
AVBP
According to ArriVent BioPharma, Inc.’s latest financial reports and current stock price. The company's current ROE is -48.98%. This represents a change of 300.06% compared to the average of -12.24% of the last 4 quarters.
The mean historical ROE of ArriVent BioPharma, Inc. over the last ten years is -55.51%. The current -48.98% ROE has changed -11.76% with respect to the historical average. Over the past ten years (40 quarters), AVBP's ROE was at its highest in in the June 2022 quarter at 0%. The ROE was at its lowest in in the March 2025 quarter at -31.79%.
Average
-55.51%
Median
-45.83%
Minimum
-125.19%
Maximum
-21.15%
Discovering the peaks and valleys of ArriVent BioPharma, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 116.63%
Maximum Annual ROE = -21.15%
Minimum Annual Increase = -83.10%
Minimum Annual ROE = -125.19%
| Year | ROE | Change |
|---|---|---|
| 2025 | -54.13% | 73.29% |
| 2024 | -31.24% | -31.83% |
| 2023 | -45.83% | 116.63% |
| 2022 | -21.15% | -83.10% |
The current ROE of ArriVent BioPharma, Inc. (AVBP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-43.73%
5-year avg
-55.51%
10-year avg
-55.51%
ArriVent BioPharma, Inc.’s ROE is less than MeiraGTx Holdings plc (474.91%), greater than Replimune Group, Inc. (-128.57%), greater than Astria Therapeutics, Inc. (-37.70%), greater than MBX Biosciences, Inc. Common Stock (-24.50%), greater than Ginkgo Bioworks Holdings, Inc. (-57.31%), greater than Iovance Biotherapeutics, Inc. (-50.17%), greater than Valneva SE (-106.22%), greater than Erasca, Inc. (-77.01%), less than Arvinas, Inc. (1.91%), greater than Day One Biopharmaceuticals, Inc. (-23.43%),
| Company | ROE | Market cap |
|---|---|---|
| 474.91% | $1.15B | |
| -128.57% | $1.01B | |
| -37.70% | $718.13M | |
| -24.50% | $3.25B | |
| -57.31% | $606.86M | |
| -50.17% | $2.00B | |
| -106.22% | $499.72M | |
| -77.01% | $6.45B | |
| 1.91% | $547.14M | |
| -23.43% | $2.22B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ArriVent BioPharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ArriVent BioPharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is ArriVent BioPharma, Inc.'s ROE?
How is the ROE calculated for ArriVent BioPharma, Inc. (AVBP)?
What is the highest ROE for ArriVent BioPharma, Inc. (AVBP)?
What is the 3-year average ROE for ArriVent BioPharma, Inc. (AVBP)?
What is the 5-year average ROE for ArriVent BioPharma, Inc. (AVBP)?
How does the current ROE for ArriVent BioPharma, Inc. (AVBP) compare to its historical average?